Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Cyst Fibros ; 20(5): 747-753, 2021 09.
Article in English | MEDLINE | ID: mdl-33549519

ABSTRACT

BACKGROUND: Treatment with Ivacaftor provides a significant clinical benefit in people with cystic fibrosis (PWCF) with the class III G551D-CFTR mutation. This study determined the effect of CFTR modulation with ivacaftor on the lung microbiota in PWCF. METHODS: Using both extended-culture and culture-independent molecular methods, we analysed the lower airway microbiota of 14 PWCF, prior to commencing ivacaftor treatment and at the last available visit within the following year. We determined total bacterial and Pseudomonas aeruginosa densities by both culture and qPCR, assessed ecological parameters and community structure and compared these with biomarkers of inflammation and clinical outcomes. RESULTS: Significant improvement in FEV1, BMI, sweat chloride and levels of circulating inflammatory biomarkers were observed POST-ivacaftor treatment. Extended-culture demonstrated a higher density of strict anaerobic bacteria (p = 0.024), richness (p = 1.59*10-4) and diversity (p = 0.003) POST-treatment. No significant difference in fold change was observed by qPCR for either total bacterial 16S rRNA copy number or P. aeruginosa density for oprL copy number with treatment. Culture-independent (MiSeq) analysis revealed a significant increase in richness (p = 0.03) and a trend towards increased diversity (p = 0.07). Moreover, improvement in lung function, richness and diversity displayed an inverse correlation with the main markers of inflammation (p < 0.05). CONCLUSIONS: Following treatment with ivacaftor, significant improvements in clinical parameters were seen. Despite modest changes in overall microbial community composition, there was a shift towards a bacterial ecology associated with less severe CF lung disease. Furthermore, a significant correlation was observed between richness and diversity and levels of circulating inflammatory markers.


Subject(s)
Aminophenols/therapeutic use , Cystic Fibrosis/drug therapy , Cystic Fibrosis/microbiology , Microbiota/drug effects , Quinolones/therapeutic use , Adolescent , Adult , Chloride Channel Agonists/therapeutic use , Cystic Fibrosis Transmembrane Conductance Regulator , Female , Humans , Male , Respiratory Function Tests , Sputum/microbiology , Young Adult
2.
Chest ; 153(2): 395-403, 2018 02.
Article in English | MEDLINE | ID: mdl-29037527

ABSTRACT

BACKGROUND: Ivacaftor produces significant clinical benefit in patients with cystic fibrosis (CF) with the G551D mutation. Prevalence of this mutation at the Cork CF Centre is 23%. This study assessed the impact of cystic fibrosis transmembrane conductance regulator modulation on multiple modalities of patient assessment. METHODS: Thirty-three patients with the G551D mutation were assessed at baseline and prospectively every 3 months for 1 year after initiation of ivacaftor. Change in ultra-low-dose chest CT scans, blood inflammatory mediators, and the sputum microbiome were assessed. RESULTS: Significant improvements in FEV1, BMI, and sweat chloride levels were observed post-ivacaftor treatment. Improvement in ultra-low-dose CT imaging scores were observed after treatment, with significant mean reductions in total Bhalla score (P < .01), peribronchial thickening (P = .035), and extent of mucous plugging (P < .001). Reductions in circulating inflammatory markers, including interleukin (IL)-1ß, IL-6, and IL-8 were demonstrated. There was a 30% reduction in the relative abundance of Pseudomonas species and an increase in the relative abundance of bacteria associated with more stable community structures. Posttreatment community richness increased significantly (P = .03). CONCLUSIONS: Early and sustained improvements on ultra-low-dose CT scores suggest it may be a useful method of evaluating treatment response. It paralleled improvement in symptoms, circulating inflammatory markers, and changes in the lung microbiota.


Subject(s)
Aminophenols/therapeutic use , Chloride Channel Agonists/therapeutic use , Cystic Fibrosis/drug therapy , Quinolones/therapeutic use , Adolescent , Adult , Cystic Fibrosis/diagnostic imaging , Cystic Fibrosis/genetics , Cystic Fibrosis/physiopathology , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Female , Forced Expiratory Volume/physiology , Humans , Male , Prospective Studies , Radiography, Thoracic/methods , Saliva/microbiology , Tomography, X-Ray Computed/methods , Young Adult
3.
Crit Rev Microbiol ; 43(4): 508-519, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28068853

ABSTRACT

One of the most common and most severe forms of primary antibody deficiency encountered in the clinical setting is a heterogeneous group of syndromes termed common variable immune deficiency (CVID). This disorder is characterized by reduced immunoglobulin production and increased susceptibility to infection, particularly of the respiratory tract. Infection and subsequent immunological/inflammatory processes may contribute to the development of pulmonary complications such as bronchiectasis and interstitial lung disease. Immunoglobulin replacement and/or antibiotic therapy, to prevent infection, are routinely prescribed treatments. However, chronic lung disease, the major cause of morbidity and mortality in this patient cohort, may still progress. This clinical progression suggests that pathogens recalcitrant to currently prescribed treatments and other immunological defects may be contributing to the development of pulmonary disease. This review describes the potential role of microbiological and non-B cell immunological factors, including T-cells, neutrophils, complement, toll like receptors, and antimicrobial peptides, in the pathogenicity of chronic lung disease in patients with CVID.


Subject(s)
Bacterial Infections/pathology , Bronchiectasis/pathology , Common Variable Immunodeficiency/pathology , Lung Diseases, Interstitial/pathology , Respiratory Tract Infections/pathology , Virus Diseases/pathology , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/immunology , Bronchiectasis/immunology , Chronic Disease , Common Variable Immunodeficiency/diagnosis , Complement System Proteins/immunology , Disease Progression , Humans , Immunologic Factors/immunology , Lung Diseases, Interstitial/immunology , Neutrophils/immunology , Respiratory Tract Infections/immunology , Respiratory Tract Infections/microbiology , T-Lymphocytes/immunology , Virus Diseases/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...